company background image

Paul Hartmann DB:PHH2 Stock Report

Last Price


Market Cap







26 Jun, 2022


Company Financials
PHH2 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance2/6
Financial Health6/6

PHH2 Stock Overview

Paul Hartmann AG manufactures and sells medical and care products in Europe, Africa, Asia, and Oceania.

Paul Hartmann Competitors













Price History & Performance

Summary of all time highs, changes and price drops for Paul Hartmann
Historical stock prices
Current Share Price€308.00
52 Week High€374.00
52 Week Low€308.00
1 Month Change-3.45%
3 Month Change-3.75%
1 Year Change-15.62%
3 Year Change3.36%
5 Year Change-28.37%
Change since IPO158.33%

Recent News & Updates

Apr 02
Here's Why Paul Hartmann (FRA:PHH2) Can Manage Its Debt Responsibly

Here's Why Paul Hartmann (FRA:PHH2) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Mar 09
Paul Hartmann (FRA:PHH2) Shareholders Will Want The ROCE Trajectory To Continue

Paul Hartmann (FRA:PHH2) Shareholders Will Want The ROCE Trajectory To Continue

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...

Nov 24
Is Paul Hartmann (FRA:PHH2) Using Too Much Debt?

Is Paul Hartmann (FRA:PHH2) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

PHH2DE Medical EquipmentDE Market

Return vs Industry: PHH2 exceeded the German Medical Equipment industry which returned -17.1% over the past year.

Return vs Market: PHH2 exceeded the German Market which returned -22% over the past year.

Price Volatility

Is PHH2's price volatile compared to industry and market?
PHH2 volatility
PHH2 Average Weekly Movement3.6%
Medical Equipment Industry Average Movement6.5%
Market Average Movement5.6%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.9%

Stable Share Price: PHH2 is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PHH2's weekly volatility (4%) has been stable over the past year.

About the Company

181810,628Britta Fuenfstueck

Paul Hartmann AG manufactures and sells medical and care products in Europe, Africa, Asia, and Oceania. It offers disinfectant products for hands, surface, and instruments; cleaning, skin care, and skin antisepsis products, as well as Sterillium, a hand disinfectant; incontinence management products; and personal healthcare products, such as diagnostic devices and first aid products. The company also provides single-use and pre-surgical products, disposable surgical gloves, clothing and gowns, and disposable drapes for use in operating theatres, treatment rooms, and wards; and wound management solutions, including traditional compresses, bandages, hydro therapy products.

Paul Hartmann Fundamentals Summary

How do Paul Hartmann's earnings and revenue compare to its market cap?
PHH2 fundamental statistics
Market Cap€1.09b
Earnings (TTM)€94.67m
Revenue (TTM)€2.31b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PHH2 income statement (TTM)
Cost of Revenue€1.03b
Gross Profit€1.28b
Other Expenses€1.19b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)26.66
Gross Margin55.45%
Net Profit Margin4.10%
Debt/Equity Ratio1.0%

How did PHH2 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is PHH2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHH2?

Other financial metrics that can be useful for relative valuation.

PHH2 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.5x
Enterprise Value/EBITDA5.1x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does PHH2's PE Ratio compare to its peers?

PHH2 PE Ratio vs Peers
The above table shows the PE ratio for PHH2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average32.4x

Price-To-Earnings vs Peers: PHH2 is good value based on its Price-To-Earnings Ratio (11.6x) compared to the peer average (32.4x).

Price to Earnings Ratio vs Industry

How does PHH2's PE Ratio compare vs other companies in the Medical Equipment Industry?

Price-To-Earnings vs Industry: PHH2 is good value based on its Price-To-Earnings Ratio (11.6x) compared to the German Medical Equipment industry average (27.9x)

Price to Earnings Ratio vs Fair Ratio

What is PHH2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHH2 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PHH2's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of PHH2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PHH2 (€308) is trading above our estimate of fair value (€205.02)

Significantly Below Fair Value: PHH2 is trading above our estimate of fair value.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PHH2's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Paul Hartmann forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Paul Hartmann has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine Paul Hartmann's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Paul Hartmann competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Paul Hartmann performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PHH2 has high quality earnings.

Growing Profit Margin: PHH2's current net profit margins (4.1%) are lower than last year (4.4%).

Past Earnings Growth Analysis

Earnings Trend: PHH2's earnings have grown by 3.7% per year over the past 5 years.

Accelerating Growth: PHH2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PHH2 had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (1.3%).

Return on Equity

High ROE: PHH2's Return on Equity (8.9%) is considered low.

Discover strong past performing companies

Financial Health

How is Paul Hartmann's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PHH2's short term assets (€989.5M) exceed its short term liabilities (€456.2M).

Long Term Liabilities: PHH2's short term assets (€989.5M) exceed its long term liabilities (€275.9M).

Debt to Equity History and Analysis

Debt Level: PHH2 has more cash than its total debt.

Reducing Debt: PHH2's debt to equity ratio has reduced from 2.7% to 1% over the past 5 years.

Debt Coverage: PHH2's debt is well covered by operating cash flow (1229.4%).

Interest Coverage: PHH2 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Paul Hartmann current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: PHH2's dividend (2.6%) is higher than the bottom 25% of dividend payers in the German market (1.47%).

High Dividend: PHH2's dividend (2.6%) is low compared to the top 25% of dividend payers in the German market (4.53%).

Stability and Growth of Payments

Stable Dividend: PHH2's dividends per share have been stable in the past 10 years.

Growing Dividend: PHH2's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (30%), PHH2's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (2123.6%), PHH2's dividend payments are not well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Britta Fuenfstueck (42 yo)



Ms. Britta Fuenfstueck has been Chief Executive Officer at Paul Hartmann AG since January 1, 2019 and its Management Board Member since January 1, 2019 and has been its Chairwoman of Management Board since...

Leadership Team

Experienced Management: PHH2's management team is seasoned and experienced (6.2 years average tenure).

Board Members

Experienced Board: PHH2's board of directors are seasoned and experienced ( 14.2 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Paul Hartmann AG's employee growth, exchange listings and data sources

Key Information

  • Name: Paul Hartmann AG
  • Ticker: PHH2
  • Exchange: DB
  • Founded: 1818
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: €1.094b
  • Shares outstanding: 3.55m
  • Website:

Number of Employees


  • Paul Hartmann AG
  • Paul-Hartmann-Straße 12
  • Heidenheim
  • Baden-Württemberg
  • 89522
  • Germany


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.